Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine
Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved vaccines used in the study.
"Combination vaccines could lessen the impact of respiratory viruses on health systems and pharmacies, while also giving people more convenient vaccination choices that might boost compliance and offer better protection against seasonal illnesses," stated Stéphane Bancel, CEO of Moderna. "Moderna stands alone with a successfu...